Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2015-01-05 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release titled 'RedHill Biopharma Business Outlook and Anticipated Key Milestones for 2015'. The document length is 2274 characters, which is relatively short and primarily serves as an announcement of information rather than a full report. Form 6-K filings typically provide current reports or updates but do not contain comprehensive financial statements or detailed analysis like annual or interim reports. The content here is a business outlook and milestone announcement, not a full financial report or earnings release. Therefore, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2015-01-05 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about the acceptance for review of a European marketing application. The document is relatively short (2321 characters) and primarily serves as an announcement rather than a detailed financial report. It does not contain financial statements or detailed analysis. Form 6-K filings are typically regulatory filings for foreign issuers to report material information between annual reports. Therefore, this document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not meet criteria for other specific report types.
2014-12-31 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release about a technology acquisition related to a clinical program. The document is short (2325 characters) and primarily serves as a regulatory announcement rather than a full financial report or detailed filing. It does not contain financial statements, management discussion, or detailed financial data. According to the rules, Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-12-18 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about clinical trial enrollment but does not contain financial statements or detailed financial analysis. The document length is short (2336 characters) and it primarily serves as a regulatory announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a certification or officer attestation. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2014-12-17 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about submitting a European Marketing Authorization Application for a product. The document is short (2315 characters) and primarily serves as an announcement of a press release rather than containing detailed financial data or comprehensive report content. Form 6-K filings are periodic reports for foreign private issuers to disclose material information and are generally classified under Regulatory Filings (RNS) as they do not fit into other specific report categories like Annual Report or Interim Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-12-09 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about sponsoring and exhibiting a Phase III Crohn's program at a medical meeting. The document is short (2318 characters) and primarily serves as a regulatory update with a press release attached. It does not contain financial statements, detailed financial analysis, or management discussion. It is not an annual report, earnings release, or detailed investor presentation. It is a regulatory filing providing current information but not a full report or announcement of voting results, capital changes, or management changes. Therefore, it fits best under Regulatory Filings (RNS).
2014-12-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.